苦参素联合恩替卡韦治疗乙型肝炎肝硬化的临床效果观察

Clinical effect observation of oxymatrine combined with entecavir in the treatment of HBV-related hepatocirrhosis

目的探究苦参素联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效,并分析其作用机制。方法 75例乙型肝炎肝硬化患者,随机分为对照组37例,观察组38例。对照组采用临床上常规用药恩替卡韦对患者进行治疗;观察组在对照组基础上加苦参素治疗。记录两组患者治疗前后体内的肝纤维化情况,并对记录结果进行统计学的处理分析。结果两组患者经治疗后,体内的肝纤维化程度都有大幅度下降,且治疗结束后,观察组的肝纤维化的水平明显要小于对照组,差异具有统计学意义(P<0.05)。结论采用苦参素联合恩替卡韦来治疗乙型肝炎肝硬化,能有效缓解乙型肝炎肝硬化情况,降低患者体内肝纤维程度,临床疗效显著,应当引起广大医学卫生工作者的重视。

Objective To investigate the clinical effect of oxymatrine combined with entecavir in the treatment of HBV-related hepatocirrhosis, and to analyze its mechanism. Methods A total of 75 patients with HBV-related hepatocirrhosis were randomly divided into control group with 37 cases and observation group with 38 cases. The control group received common clinical treatment by entecavir, and the observation group received additional oxymatrine for treatment. Conditions of hepatic fibrosis in the two groups were recorded before and after treatment for statistical analysis. Results After treatment, both groups had obviously decreased hepatic fibrosis. The observation group had much lower hepatic fibrosis level than the control group, and their difference had statistical significance （P〈0.05）. Conclusion Combination of oxymatrine and entecavir for treating HBV-related hepatocirrhosis can effectively relieve condition of HBV-related hepatocirrhosis and reduce hepatic fibrosis level. It contains significant clinical effect, and is worthy of wide attention from medical workers.